Zogenix, Inc. (NASDAQ:ZGNX) Director Mark C. Wiggins bought 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was purchased at an average cost of $23.19 per share, for a total transaction of $57,975.00. Following the completion of the transaction, the director now owns 2,500 shares in the company, valued at $57,975. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of ZGNX opened at $23.66 on Friday. The business’s 50-day moving average is $27.14 and its two-hundred day moving average is $41.91. The company has a market capitalization of $1.08 billion, a P/E ratio of -2.43 and a beta of 2.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.01 and a current ratio of 3.01. Zogenix, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $57.22.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.20). The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $0.49 million. During the same quarter in the prior year, the company earned ($0.53) earnings per share. Analysts forecast that Zogenix, Inc. will post -4.03 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in ZGNX. Strs Ohio acquired a new stake in shares of Zogenix during the 4th quarter valued at about $36,000. Meeder Asset Management Inc. acquired a new stake in shares of Zogenix during the 4th quarter valued at about $66,000. Russell Investments Group Ltd. acquired a new stake in shares of Zogenix during the 3rd quarter valued at about $80,000. Quantbot Technologies LP acquired a new stake in shares of Zogenix during the 4th quarter valued at about $118,000. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Zogenix during the 1st quarter valued at about $193,000.
Several research firms recently issued reports on ZGNX. Zacks Investment Research reissued a “buy” rating and issued a $63.00 target price on shares of Zogenix in a research report on Saturday, January 25th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 13th. Citigroup began coverage on Zogenix in a research report on Thursday, March 5th. They issued a “neutral” rating and a $27.00 target price on the stock. Mizuho reissued a “buy” rating and issued a $65.00 target price on shares of Zogenix in a research report on Tuesday, December 10th. Finally, BidaskClub downgraded Zogenix from a “buy” rating to a “hold” rating in a research report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $57.64.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Article: Reverse Stock Split
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.